AP805A - Process for substituted pyridines. - Google Patents

Process for substituted pyridines. Download PDF

Info

Publication number
AP805A
AP805A APAP/P/1997/001147A AP9701147A AP805A AP 805 A AP805 A AP 805A AP 9701147 A AP9701147 A AP 9701147A AP 805 A AP805 A AP 805A
Authority
AP
ARIPO
Prior art keywords
alkyl
compound
independently
formula
group
Prior art date
Application number
APAP/P/1997/001147A
Other languages
English (en)
Other versions
AP9701147A0 (en
Inventor
Vries Keith Michael De
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AP9701147A0 publication Critical patent/AP9701147A0/xx
Application granted granted Critical
Publication of AP805A publication Critical patent/AP805A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
APAP/P/1997/001147A 1996-11-14 1997-11-13 Process for substituted pyridines. AP805A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (2)

Publication Number Publication Date
AP9701147A0 AP9701147A0 (en) 1998-01-31
AP805A true AP805A (en) 2000-01-28

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001147A AP805A (en) 1996-11-14 1997-11-13 Process for substituted pyridines.

Country Status (32)

Country Link
US (1) US6291489B1 (de)
EP (1) EP0938476B1 (de)
JP (1) JP3510635B2 (de)
KR (1) KR20000053314A (de)
CN (1) CN1237160A (de)
AP (1) AP805A (de)
AR (1) AR010584A1 (de)
AT (1) ATE319687T1 (de)
AU (1) AU4634697A (de)
BG (1) BG103393A (de)
BR (1) BR9712951A (de)
CA (1) CA2270386C (de)
CO (1) CO4930261A1 (de)
DE (1) DE69735433D1 (de)
EA (1) EA199900375A1 (de)
GT (1) GT199700118A (de)
HR (1) HRP970612A2 (de)
ID (1) ID18898A (de)
IL (1) IL129688A0 (de)
IS (1) IS5029A (de)
MA (1) MA24401A1 (de)
MY (1) MY132507A (de)
NO (1) NO992296D0 (de)
OA (1) OA11044A (de)
PA (1) PA8441401A1 (de)
PE (1) PE10299A1 (de)
TN (1) TNSN97172A1 (de)
TR (1) TR199901063T2 (de)
UY (1) UY24774A1 (de)
WO (1) WO1998021184A1 (de)
YU (1) YU22099A (de)
ZA (1) ZA9710186B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909555A (pt) * 1998-04-08 2000-12-19 Novartis Ag Novartis S A Novar Herbicidas
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
KR20010102198A (ko) * 1999-02-16 2001-11-15 후루타 타케시 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
EP1078924B1 (de) * 1999-07-23 2004-10-20 Pfizer Products Inc. Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
JPWO2003033468A1 (ja) * 2001-10-17 2005-02-03 株式会社カネカ (S)−α−ハロメチルピリジンメタノール誘導体の製造方法
MXPA04008298A (es) 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
EP1424079A1 (de) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Kombination eines beta-3-Rezeptoragonisten und eines Serotonin und/oder Norepinephrin-Wiederaufnahmeinhibitors
KR100751163B1 (ko) 2003-05-09 2007-08-22 에프. 호프만-라 로슈 아게 알파-1 아드레날린 작용물질로서의 메틸 인돌 및 메틸피롤로피리딘
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US20110160249A1 (en) 2008-05-23 2011-06-30 Schaab Kevin Murray 5-lipoxygenase-activating protein inhibitor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029290A1 (en) * 1993-06-14 1994-12-22 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
EP0828712A1 (de) 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergische agonisten
JPH11504649A (ja) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作働性アゴニスト

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029290A1 (en) * 1993-06-14 1994-12-22 Pfizer Inc. Secondary amines as antidiabetic and antiobesity agents
WO1995029159A1 (en) * 1994-04-26 1995-11-02 Merck & Co., Inc. SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY

Also Published As

Publication number Publication date
US6291489B1 (en) 2001-09-18
CA2270386A1 (en) 1998-05-22
CA2270386C (en) 2004-08-03
TNSN97172A1 (fr) 2005-03-15
AU4634697A (en) 1998-06-03
ID18898A (id) 1998-05-20
HRP970612A2 (en) 1998-08-31
CO4930261A1 (es) 2000-06-27
UY24774A1 (es) 1998-05-05
EP0938476A1 (de) 1999-09-01
YU22099A (sh) 2001-09-28
AP9701147A0 (en) 1998-01-31
JP3510635B2 (ja) 2004-03-29
TR199901063T2 (xx) 1999-08-23
CN1237160A (zh) 1999-12-01
BR9712951A (pt) 1999-12-07
ZA9710186B (en) 1999-05-12
MY132507A (en) 2007-10-31
PA8441401A1 (es) 2000-05-24
KR20000053314A (ko) 2000-08-25
NO992296L (no) 1999-05-12
PE10299A1 (es) 1999-02-10
ATE319687T1 (de) 2006-03-15
AR010584A1 (es) 2000-06-28
NO992296D0 (no) 1999-05-12
IS5029A (is) 1999-04-16
OA11044A (en) 2002-02-20
MA24401A1 (fr) 1998-07-01
EP0938476B1 (de) 2006-03-08
DE69735433D1 (de) 2006-05-04
IL129688A0 (en) 2000-02-29
JP2000504347A (ja) 2000-04-11
WO1998021184A1 (en) 1998-05-22
GT199700118A (es) 1999-05-05
EA199900375A1 (ru) 1999-12-29
BG103393A (en) 2000-07-31

Similar Documents

Publication Publication Date Title
AP805A (en) Process for substituted pyridines.
US6031105A (en) Substituted pyridines
CN114591308B (zh) 一类glp-1r受体激动剂化合物及其用途
JP2000516593A (ja) 糖尿病及び肥満症の治療に用いられる選択的β▲下3▼作動物質としての置換スルホンアミド
EP0698022B1 (de) 1,4-benzoxazinderivate als kalium kanalaktivatoren
JPH0283375A (ja) 2−置換ピペラジニル−2−(1,2−ベンズイソキサゾール−3−イル)酢酸誘導体
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
WO2017202357A1 (zh) 一种三氟甲基取代的吡喃衍生物的制备方法
KR102611847B1 (ko) 무스카린 수용체 길항 활성을 갖는 신규한 피롤리디늄 화합물 및 이의 용도
CN113278012A (zh) 用作激酶抑制剂的化合物及其应用
US6124457A (en) Process and intermediates for a β3 -adrenergic receptor agonist
JP3213576B2 (ja) 置換ピリジン
MXPA99004459A (en) Process for substituted pyridines
US6008361A (en) Substituted pyridines
CZ169499A3 (cs) Způsoby výroby substituovaných pyridinů
JPS6350343B2 (de)
JPH037279A (ja) 2―チオピランカルボチオアミド誘導体
JPH024791A (ja) ピラノベンゾトリアゾール誘導体
CN117321053A (zh) P300抑制剂及其在医药上的应用
JPS62221680A (ja) フエノキシアルキルアミン側鎖を有するベンゾチアゾリン誘導体
TW403744B (en) Piperidinyl compounds
JP2002332287A (ja) 五環性タキサン化合物およびその製造方法
MXPA99009446A (en) Procedure and intermediates for a receptor agonist b3 adrenerg
AU5400999A (en) Process and intermediates for A beta 3-adrenergic receptor agonist
CZ9903636A3 (cs) Způsob a meziprodukty pro beta3-adrenergický receptorový agonist